摘要
Ivermectin is a widely used antiparasitic drug and shows promising anticancer activity in various cancer types. Although multiple signaling pathways modulated by ivermectin have been identified in tumor cells, few studies have focused on the exact target of ivermectin. Herein, we report the pharmacological effects and targets of ivermectin in prostate cancer. Ivermectin caused G0/G1 cell cycle arrest, induced cell apoptosis and DNA damage, and decreased androgen receptor (AR) signaling in prostate cancer cells. Further in vivo analysis showed ivermectin could suppress 22RV1 xenograft progression. Using integrated omics profiling, including RNA-seq and thermal proteome profiling, the forkhead box protein A1 (FOXA1) and non-homologous end joining (NHEJ) repair executer Ku70/Ku80 were strongly suggested as direct targets of ivermectin in prostate cancer. The interaction of ivermectin and FOXA1 reduced the chromatin accessibility of AR signaling and the G0/G1 cell cycle regulator E2F1, leading to cell proliferation inhibition. The interaction of ivermectin and Ku70/Ku80 impaired the NHEJ repair ability. Cooperating with the downregulation of homologous recombination repair ability after AR signaling inhibition, ivermectin increased intracellular DNA double-strand breaks and finally triggered cell death. Our findings demonstrate the anticancer effect of ivermectin in prostate cancer, indicating that its use may be a new therapeutic approach for prostate cancer.
学科与关键词
- Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancerWang, Shan*; Gilbreath, Collin; Kollipara, Rahul K.; Sonavane, Rajni; Huo, Xiaofang; Yenerall, Paul; Das, Amit; Ma, Shihong; Raj, Ganesh, V; Kittler, Ralf*Cancer Letters, 2020, 488: 40-49.
- Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.Chatterjee Payel; Schweizer Michael T; Lucas Jared M; Coleman Ilsa; Nyquist Michael D; Frank Sander B; Tharakan Robin; Mostaghel Elahe; Luo Jun; Pritchard Colin C; Lam Hung Ming; Corey Eva; Antonarakis Emmanuel S; Denmeade Samuel R; Nelson Peter SJournal of Clinical Investigation, 2019, 130.
- Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancerZhou, Xumin; Zou, Libin; Chen, Wenbin; Yang, Taowei; Luo, Junqi; Wu, Kaihui; Shu, Fangpeng; Tan, Xiao; Yang, Yu; Cen, Shengren; Li, Chuanyin*; Mao, Xiangming*Pharmacological Research, 2021, 164: 105305.被引 41
